logo
Global Initiative Launched To Protect Kidney Patients During Crises and Emergencies

Global Initiative Launched To Protect Kidney Patients During Crises and Emergencies

May 22, 2025 /3BL/ - An international alliance of humanitarian and medical organizations is announcing the launch of a new initiative to protect kidney and dialysis patients in crisis settings around the world.
The Global Humanitarian Kidney Support Initiative—a collaboration among Direct Relief, the American Society of Nephrology (ASN), the European Renal Association (ERA), and the International Society of Nephrology (ISN)—aims to ensure continuity of care for people with serious kidney conditions during disasters, conflicts, and in regions where access to essential health services is limited.
The initiative brings together global clinical expertise in nephrology with on-the-ground experience in humanitarian logistics to help sustain kidney care when health systems are disrupted or overwhelmed.
Kidney patients—particularly those receiving dialysis or post-transplant care requiring essential medications—are especially vulnerable in emergencies. Regular access to treatment is essential for survival, and any interruption can quickly become life-threatening. The initiative seeks to address that risk through coordinated action, including emergency support for clinics and hospitals, provision of essential medicines and supplies, and training for healthcare workers operating under strained conditions.
'Kidney patients rely on consistent, life-sustaining treatment, which can be difficult to maintain when disaster strikes,' said Alycia Clark, Chief Pharmacist at Direct Relief. 'This collaboration helps ensure continuity of care by equipping health facilities with the products, training, and coordination required to deliver treatment safely and effectively—even under the most challenging conditions.'
The partner organizations have previously worked together during major emergencies in the United States, Ukraine, Sudan, and other regions. The launch of this initiative builds on those efforts and establishes a formal structure to improve speed, coordination, and scale in future responses.
'This initiative reflects how much more can be accomplished when organizations combine strengths with a shared commitment to meeting urgent medical needs,' said Amy Weaver, CEO of Direct Relief. 'By uniting nephrology leaders with expertise in humanitarian operations, this collaboration creates a clear path for delivering kidney care where it's most at risk of falling through the cracks.'
In addition to emergency response, the Global Humanitarian Kidney Support Initiative aims to contribute to long-term improvements in care by strengthening infrastructure in low- and middle-income countries, expanding clinical education, and advancing patient awareness and disease prevention strategies. Direct Relief will manage medical supply logistics and operational support, while ASN, ERA, and ISN will lead regional efforts through their professional networks and national society partners.
'ASN is thrilled to be part of this new collaboration with ERA, ISN and Direct Relief. Together, we will be able to provide support to patients and their caregivers in regions impacted by both natural and human-influenced events and stretch each organization's resources further. The support of corporate and foundation sponsors will be instrumental in ensuring that people living with kidney diseases have the best chance to thrive even in extreme circumstances', said Jeffrey Silberzweig, MD, Chair, ASN's Humanitarian Kidney Support Program
'Patients with kidney diseases represent one of the most vulnerable groups in disaster settings since their survival depends on functional infrastructure, access to advanced technology and experienced personnel within days (if not hours),' said Professor Mehmet Şükrü Sever, Chair of ERA's Kidney Relief in Disasters Task Force. The Global Humanitarian Kidney Support Initiative can contribute to life-saving efforts by promoting clinical education, enhancing patient awareness and disease prevention strategies and delivering material support when most needed.
'Kidney patients in many parts of the world already have fragile access to care. When disaster strikes, the risk of interruption or disruption of needed care becomes rapidly acute. This initiative strengthens collaboration between professional renal societies and humanitarian organizations, allowing the ISN to contribute its expertise and help connect local providers with urgently needed support', stated Prof. Ali Abu-Alfa, Chair, ISN Renal Disaster Preparedness Working Group.
Looking ahead, the initiative aims to expand its reach and impact by engaging pharmaceutical and medical device companies, philanthropic foundations, and global health partners to close critical gaps in care and strengthen long-term support for people living with kidney disease—especially in regions where treatment access remains fragile.
###
About ASN
Since 1966, ASN has been leading the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge and advocating for the highest quality care for patients. ASN has nearly 22,000 members representing 141 countries. For more information, visit www.asn-online.org and follow us on Facebook, X, LinkedIn, and Instagram
About Direct Relief
A humanitarian organization committed to improving the health and lives of people affected by poverty or emergencies, Direct Relief delivers lifesaving medical resources to communities in need around the world—without regard to politics, religion, or ability to pay. The organization holds NABP Drug Distributor Accreditation and is licensed to distribute prescription medications in all 50 U.S. states. In 2025, Direct Relief received the Seoul Peace Prize in recognition of its global humanitarian impact and effectiveness. For more information, please visit www.DirectRelief.org.
About ERA
With more than 28,000 members, the ERA (European Renal Association) is one of the largest and most prestigious nephrology associations worldwide. It supports basic and clinical research in clinical nephrology, dialysis, renal transplantation, and related subjects, dedicated to advancing kidney health through science, education, and networking. Founded in 1963, ERA serves as a leading platform for scientific exchange, professional development, and advocacy in the field of nephrology across Europe and beyond. ERA organises annual congresses, supports fellowships and CME courses, and publishes two leading nephrology journals in Europe: Nephrology Dialysis Transplantation and Clinical Kidney Journal (open access). For more information, please visit https://www.era-online.org/
About ISN
The International Society of Nephrology, established in 1960, is a global professional medical association committed to advancing kidney health worldwide through education, grants, research, and advocacy. By collaborating with its members and affiliated national and regional societies, the ISN engages with 30,000 health professionals worldwide to help reduce the burden of kidney diseases and provide optimal health care for patients globally. For more information, please visit https://www.theisn.org/
Visit 3BL Media to see more multimedia and stories from Direct Relief
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Buyout giant Warburg Pincus snaps up Health Partners stake
Buyout giant Warburg Pincus snaps up Health Partners stake

Yahoo

time13 minutes ago

  • Yahoo

Buyout giant Warburg Pincus snaps up Health Partners stake

One of the world's biggest private equity firms has agreed to acquire a stake in Health Partners Group, a provider of occupational health services to millions of its clients' employees. Sky News understands that Warburg Pincus has struck a deal to partner with the company in a deal valuing it at more than £300m. Health Partners Group was founded in 2016 by chief executive Andrew Noble and chief medical officer Dr Alasdair Emslie. Money latest: It is principally focused on serving private sector clients, although it does not disclose their identities. In the year to July 31, 2024, it reported revenue of close to £77m and earnings before interest, tax, depreciation and amortisation of £13.6m, according to accounts filed at Companies House. The company says it is now the largest occupational health provider and among the largest non-hospital healthcare providers in Britain. Further details of the transaction with Warburg Pincus, including the size of the stake it had agreed to buy, were unclear on Monday. The deal is said by bankers to value Health Partners at between £300m and £400m. Warburg Pincus has backed similar businesses in other countries, including Quantum Health in the US and Arsipa in Europe. On Monday, Warburg Pincus declined to comment.

Cutting-edge Diagnostic Technologies Transforming $6.4 Billion Landscape
Cutting-edge Diagnostic Technologies Transforming $6.4 Billion Landscape

Yahoo

time13 minutes ago

  • Yahoo

Cutting-edge Diagnostic Technologies Transforming $6.4 Billion Landscape

The U.S. Alzheimer's disease diagnostics market, valued at USD 3.53 billion in 2024, is projected to grow at a CAGR of 10.6% from 2025-2030. Growth is driven by rising Alzheimer's prevalence and advanced diagnostics like FDA-approved blood tests, improving early detection and care planning. U.S. Alzheimer's Disease Diagnostics Market Dublin, July 28, 2025 (GLOBE NEWSWIRE) -- The "U.S. Alzheimer's Disease Diagnostics Market Size, Share & Trends Analysis Report By Diagnostic Technique (Biomarkers, Imaging Techniques, Genetic Testing, Cognitive Assessment Tests), By Type, By End-use, And Segment Forecasts, 2025 - 2030" report has been added to U.S. Alzheimer's disease diagnostics market was valued at USD 3.53 billion in 2024 and is expected to grow at a CAGR of 10.6% from 2025 to 2030 This growth is driven by the rising prevalence of Alzheimer's disease and increasing emphasis on early and accurate diagnosis. According to the U.S. Centers for Disease Control and Prevention (CDC), approximately 6.7 million older adults in the U.S. were living with Alzheimer's disease in 2024, a number projected to nearly double by 2060. The growing prevalence of the disease prompted government and private healthcare bodies to invest heavily in advanced diagnostic technologies such as PET imaging, cerebrospinal fluid biomarkers, and blood-based diagnostics. The growth of the U.S. Alzheimer's disease diagnostics market is due to the recent regulatory approval of advanced, non-invasive diagnostic technologies. The U.S. FDA granted marketing clearance for the first in vitro diagnostic device that utilizes a blood test to support the diagnosis of Alzheimer's disease. The Lumipulse G pTau217/b-Amyloid 1-42 Plasma Ratio is specifically intended for the early detection of amyloid plaque accumulation, a hallmark of Alzheimer's pathology, in adult patients aged 55 years and older who are exhibiting clinical signs and symptoms consistent with cognitive development represents a major advancement in Alzheimer's diagnostics, significantly lowering access barriers by providing a cost-effective and minimally invasive alternative to PET scans and lumbar punctures, which often carry procedural risks. The FDA highlighted that this approval makes it easier and potentially more accessible for U.S. patients earlier in the disease. It underscores the test's value in facilitating timely intervention and clinical decision-making in the early stages of Alzheimer's disease increasing rate of dementia diagnosis among older adults is driving the growth of the U.S. Alzheimer's diagnostics market. According to the 2022 National Health Interview Survey by the CDC, approximately 4% of individuals aged 65 and older have been diagnosed with dementia, with this figure rising to 13% among those aged 85 and above. This growth is primarily attributed to longer life expectancy, enhanced awareness, and improved diagnostic practices across clinical settings. The rising need for scalable, accurate diagnostic solutions to support early detection, appropriate intervention, and optimized care planning. Why should you buy this report? Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments. Competitive Landscape: Explore the market presence of key players worldwide. Future Trends: Discover the pivotal trends and drivers shaping the future of the global market. Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions. Key Attributes: Report Attribute Details No. of Pages 80 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $3.53 Billion Forecasted Market Value (USD) by 2030 $6.43 Billion Compound Annual Growth Rate 10.6% Regions Covered United States Competitive Landscape GE HealthCare Siemens Healthineers AG Canon Medical Systems Corporation Cerveau Technologies, Inc. Neurovision Imaging, Inc. Thermo Fisher Scientific Inc. Bio-Rad Laboratories, Inc. Quanterix Corporation Alzheon Inc. NanoSomiX, Inc. DiamiR Biosciences Company Overview Financial Performance Diagnostic Technique Portfolio Recent Developments/ Strategic Initiatives U.S. Alzheimer's Disease Diagnostics Market Report SegmentationDiagnostic Technique Outlook (Revenue, USD Million, 2018 - 2030) Biomarkers CSF Biomarkers Blood-Based Biomarkers Imaging Diagnostic Techniques Genetic Testing Cognitive Assessment Tests Type Outlook (Revenue, USD Million, 2018 - 2030) Triage Diagnosis Screening End Use Outlook (Revenue, USD Million, 2018 - 2030) Hospitals Diagnostic Laboratories Academic & Research Institutes For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment U.S. Alzheimer's Disease Diagnostics Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio

OSR Holdings to acquire South Korea's medical device company Woori IO
OSR Holdings to acquire South Korea's medical device company Woori IO

Yahoo

timean hour ago

  • Yahoo

OSR Holdings to acquire South Korea's medical device company Woori IO

Healthcare business OSR Holdings (OSRH) has signed a term sheet to acquire South Korea's medical device company, Woori IO (WORIO). Under the agreement, WORIO will be acquired by OSRH's Korean affiliate, OSR Holdings Co., Ltd (OSRK). WORIO will become OSRK's wholly owned subsidiary, with the shareholders of the former receiving new OSRK shares. These shares may be convertible into OSRH common stock on Nasdaq, subject to a $10 per OSRH share condition and other terms. WORIO shareholders have the option of converting their OSRK shares into OSRH shares at a fixed ratio. This conversion is contingent upon OSRH's stock price, hitting a minimum of $10.00 at any point within three years after the term sheet is executed. Should this price target not be achieved within the specified timeframe, both parties are committed to entering into renegotiations. A six-month exclusivity period is part of the agreement, during which OSRK will carry out confirmatory legal and financial due diligence. The goal is to conclude the acquisition within this timeframe. Via its subsidiaries, OSRH is involved in various healthcare sectors, including regenerative biologics, immuno-oncology, and the distribution of medical devices. OSRH CEO Peter Hwang said: "We believe this initial milestone with Woori IO aligns strongly with our mission to accelerate breakthrough healthcare innovations with global impact. "Woori IO's breakthrough noninvasive glucose monitoring platform, coupled with its high-profile partnership with global companies, puts OSRH in a position to become a first mover in this fast-growing global market." WORIO's platform is said to leverage near-infrared spectroscopy (NIRS) for the measurement of glucose levels, eliminating the need for finger pricks from diabetes patients. The technology has already undergone a proof-of-concept trial with the Korea University Hospital (Guro) to validate its prototype devices. WORIO is preparing for a larger confirmatory study to seek approval from the Korean Ministry of Food and Drug Safety (MFDS). The company's technology is also seen as a potential addition to wearable glucose monitoring devices such as smartwatches. "OSR Holdings to acquire South Korea's medical device company Woori IO" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store